H5N1 News and Research

Latest H5N1 News and Research

Human populations may have some level of existing immunity to the pandemic H1N1 influenza, say researchers

University of California, Davis, researchers studying the 2009 H1N1 influenza virus, formerly referred to as "swine flu," have identified a group of immunologically important sites on the virus that are also present in seasonal flu viruses that have been circulating for years. These molecular sites appear to result in some level of immunity to the new virus in people who were exposed to the earlier influenza viruses.

15 Oct 2009

Sinovac Biotech announces receipt of Panflu vaccine distribution approval in Hong Kong

Sinovac Biotech Ltd., a leading developer and provider of vaccines in China, announced today that its wholly-owned subsidiary, Sinovac Biotech (Hong Kong) Ltd, has received the Certificate of Approval to distribute Panflu(TM) (H5N1), its H5N1 (bird flu) pandemic influenza vaccine, in Hong Kong. The certificate is valid through September 13, 2014 and thereafter will be renewable for periods of five years at a time, subject to payment of the registration fee.

14 Oct 2009

Inovio Biomedical's proprietary DNA vaccine development platform introduced

Inovio Biomedical Corporation (NYSE Amex:INO), a leader in DNA vaccine design, development and delivery, announced today that Dr. J. Joseph Kim, president and CEO, presented at the invitation-only World Knowledge Forum being held in Seoul, South Korea.

14 Oct 2009

NIH awards $2.2m grant to Smiths Detection to develop a test for multiple types of influenza

Smiths Detection today announces the award of a $2.2m, two-year grant from the National Institute of Allergy and Infectious Diseases, part of the US National Institutes of Health (NIH), to develop a test for multiple types of influenza.

14 Oct 2009

Massive mismanagement leads to catastrophic decline in freshwater biodiversity

The world will miss its agreed target to stem biodiversity loss by next year, according to experts convening in Cape Town for a landmark conference devoted to biodiversity science.

13 Oct 2009

ImmuneRegen BioSciences to test efficacy of Homspera against H5N1 Avian Influenza

ImmuneRegen BioSciences, Inc.®, a wholly owned subsidiary of IR Biosciences Holdings, Inc. (OTCBB: IRBS), today announced that its lead anti-influenza drug, Homspera, will be tested for efficacy against highly lethal H5N1 Avian Influenza in the laboratories of a widely respected University scientist. Additionally, testing at an independent facility will further define the adjuvant efficacy of Homspera when coupled with a novel vaccine for H5N1 in studies sponsored by an ImmuneRegen industry partner.

12 Oct 2009

Presentations on efficacy of interferon to combat influenza

Amarillo Biosciences, Inc. (ABI) today announced that Professor Dr. Otto Haller from the Department of Virology, Freiburg University, Germany and Professor Dr. Oliver Planz from the Friedrich Loeffler Institute, Tubingen, Germany gave two separate presentations on the efficacy of interferon to combat influenza.

12 Oct 2009

Medicago receives contract from U.S. Army Research, Development and Engineering Command laboratory

Medicago Inc. (TSX-V: MDG), a biotechnology company focused on developing highly effective and affordable vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced that it has been awarded a proof of concept contract by the U.S. Army Research, Development and Engineering Command laboratory specifically the Edgewood Chemical Biological Center ("ECBC") Research & Technology Directorate.

9 Oct 2009

Experts to develop effective surveillance system to monitor emerging infections at global level

Avian influenza (H5N1), rabies, plague, Bovine Spongiform Encephalopathy (BSE), and more recently swine flu (H1N1) are all examples of diseases that have made the leap from animals to humans.

8 Oct 2009

Inviragen, SingVax merge their complementary vaccine pipelines

Inviragen and SingVax have merged their complementary vaccine pipelines and their international product development capabilities to create a company that is developing a wide range of vaccines for infectious diseases prevalent in emerging economies.

6 Oct 2009

NanoViricides completes a number of financing activities

NanoViricides, Inc. (the "Company"), announced today that it has completed a number of financing activities.

5 Oct 2009

Inovio's SynCon H1N1 achieves protective antibody response against pandemic influenza in ferrets

Inovio Biomedical Corporation, a leader in DNA vaccine design, development and delivery, announced today that a combination of its synthetic consensus (SynConTM) H1N1 influenza vaccine candidates achieved protective antibody responses against the novel pandemic influenza A/H1N1 (2009) in 100% of tested ferrets.

5 Oct 2009

Chinese government places second purchase order for Sinovac Biotech's H1N1 vaccine

Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, announced today that Sinovac has received its second purchase order for its H1N1 vaccine, PANFLU.1, from the Ministry of Industry and Information Technology of the People's Republic of China for the national stockpiling plan.

3 Oct 2009

DelSite's assests acquired by Nanotherapeutics

Nanotherapeutics, Inc., a privately held specialty biopharmaceutical company, announced today that it had acquired certain assets from DelSite (formerly Carrington Laboratories, Inc.) out of Chapter 7 bankruptcy proceedings in the U.S. Bankruptcy Court for the Northern District of Texas, Dallas Division.

3 Oct 2009

The Replikin Count of H1N1 virus’s infectivity gene shows continued elevation

The latest H1N1 genomic data shows a 50% drop in the Replikin CountTM of the virus’s replikins lethality gene since its recorded highs in April 2009. In contrast, the Replikin Count of the virus’s infectivity gene showed a continued elevation.

30 Sep 2009

Aphios awarded NIH grant to develop pathogen inactivation technology for blood products

Aphios Corporation today announced that it has been awarded a RC-1 Challenge grant (No. 1RC1HL102822-01) from the National Heart, Lung, and Blood Institute (NHLBI), National Institute of Health’s (NIH) American Recovery and Reinvestment Act (ARRA) funds to develop a generally-applicable pathogen inactivation technology for blood products.

30 Sep 2009

Drug Discovery and Development to focus on pharmaceutical trends

NanoViricides, Inc., announced today that the Company’s CEO, Eugene Seymour, MD, MPH has been invited as a panelist at the 2nd Annual Livingston Healthcare Summit on September 24th, 2009 in New York City.

24 Sep 2009

CEL-SCI Corporation engages a CRO for clinical trial of its investigational LEAPS-H1N1 treatment

CEL-SCI Corporation (NYSE AMEX: CVM), a developer of vaccines and therapeutics for the treatment of infectious diseases and a late-stage oncology company, announced today that it has hired a full-service Clinical Research Organization (CRO) with an office in the Washington, D.C./Baltimore area to support its conduct of the upcoming clinical trial of its investigational LEAPS-H1N1 treatment.

24 Sep 2009

Update from Cannabis Science regarding its phytocannabinoid pharmaceutical products

Cannabis Science Inc. (NASD OTCBB: CBIS) an emerging pharmaceutical cannabis company, is pleased to report progress for its phytocannabinoid pharmaceutical products to help reduce ARDS-associated deaths from both the Avian and Swine Influenza infections.

22 Sep 2009

Nanoviricides and Southern Research sign agreement to test anti-Influenza and anti-HIV drug candidates

NanoViricides, Inc. (OTC BB: NNVC.OB) (the "Company"), reported today that it has signed a “Master Service Agreement” with the Southern Research Institute (“Southern Research”), Birmingham, AL. Southern Research is a well established, prestigious institution that has performed preclinical testing services for several vaccines and antivirals.

21 Sep 2009

H5N1 News and Research

Latest H5N1 News and Research

Human populations may have some level of existing immunity to the pandemic H1N1 influenza, say researchers

Sinovac Biotech announces receipt of Panflu vaccine distribution approval in Hong Kong

Inovio Biomedical's proprietary DNA vaccine development platform introduced

NIH awards $2.2m grant to Smiths Detection to develop a test for multiple types of influenza

Massive mismanagement leads to catastrophic decline in freshwater biodiversity

ImmuneRegen BioSciences to test efficacy of Homspera against H5N1 Avian Influenza

Presentations on efficacy of interferon to combat influenza

Medicago receives contract from U.S. Army Research, Development and Engineering Command laboratory

Experts to develop effective surveillance system to monitor emerging infections at global level

Inviragen, SingVax merge their complementary vaccine pipelines

NanoViricides completes a number of financing activities

Inovio's SynCon H1N1 achieves protective antibody response against pandemic influenza in ferrets

Chinese government places second purchase order for Sinovac Biotech's H1N1 vaccine

DelSite's assests acquired by Nanotherapeutics

The Replikin Count of H1N1 virus’s infectivity gene shows continued elevation

Aphios awarded NIH grant to develop pathogen inactivation technology for blood products

Drug Discovery and Development to focus on pharmaceutical trends

CEL-SCI Corporation engages a CRO for clinical trial of its investigational LEAPS-H1N1 treatment

Update from Cannabis Science regarding its phytocannabinoid pharmaceutical products

Nanoviricides and Southern Research sign agreement to test anti-Influenza and anti-HIV drug candidates

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Genomic conservation in Thailand's mangroves

H5N1 News and Research

Latest H5N1 News and Research

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Genomic conservation in Thailand's mangroves

Newsletters you may be interested in